Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  ABIOMED, Inc.    ABMD

ABIOMED, INC. (ABMD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Abiomed : invests in Israeli medical device maker Magenta

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/28/2017 | 01:06pm CET

Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc (>> ABIOMED, Inc.), a maker of catheter-based heart pumps, and venture capital firm Pitango.

Israeli medical device company Magenta Medical said on Thursday it has raised $15 million in funding led by Massachusetts-based Abiomed Inc (>> ABIOMED, Inc.), a maker of catheter-based heart pumps, and venture capital firm Pitango.

Japanese venture capital group JAFCO and a group of cardiovascular experts also invested in the round.

The Israeli startup is developing an apparatus for treating acute heart failure which it says can alleviate congestion faster and more safely than diuretics alone. Heart failure afflicts approximately 6.5 million people in the United States alone.

Ehud Schwammenthal, Magenta's co-founder and chief medical officer, said the company's first product was in clinical trials in Europe. The funding, he said, will allow the firm to expand the clinical programme, with the goal of getting approval in Europe and a second study going in the United States.

(Reporting by Dan Pleck; Editing by Tova Cohen)

Stocks treated in this article : ABIOMED, Inc., Medtronic PLC
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABIOMED, INC.
11/02 ABIOMED INC : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RE..
10/28 ABIOMED : MILITARY $25,126 Federal Contract Awarded to Abiomed
10/26 ABIOMED INC : Results of Operations and Financial Condition, Financial Statement..
10/26 ABIOMED : beats Street 2Q forecasts
10/26 Abiomed Announces First Patient Treated with Impella® in Japan
10/26 ABIOMED : Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S...
10/20 ABIOMED : s Impella Technology that Enables Heart Recovery Showcased at TCT 2017..
10/19 Abiomed's Impella® Technology that Enables Heart Recovery Showcased at TCT 20..
10/10 ABIOMED : Second Quarter Fiscal 2018 Earnings and Conference Call Notification
10/09 ABIOMED : 65-- CATH LAB BPA-ABIOMED-Impella Catheters
More news
News from SeekingAlpha
11/02 YOUR DAILY PHARMA SCOOP : Teva Q3 Results, Boost For RedHill, Clovis Reports Rub..
10/31 Abiomed's big run continues after investor meeting; shares up 6.9%
10/28 ABIOMED's (ABMD) CEO Mike Minogue on Q2 2018 Results - Earnings Call Transcri..
10/28 Stocks to watch next week
10/26 Abiomed revenues up 30% in Q2; updates guidance
Financials ($)
Sales 2018 575 M
EBIT 2018 142 M
Net income 2018 109 M
Finance 2018 316 M
Yield 2018 -
P/E ratio 2018 79,59
P/E ratio 2019 72,86
EV / Sales 2018 14,2x
EV / Sales 2019 10,9x
Capitalization 8 461 M
Chart ABIOMED, INC.
Duration : Period :
ABIOMED, Inc. Technical Analysis Chart | ABMD | US0036541003 | 4-Traders
Technical analysis trends ABIOMED, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 194 $
Spread / Average Target 1,6%
EPS Revisions
Managers
NameTitle
Michael R. Minogue Chairman, President & Chief Executive Officer
David M. Weber Chief Operating Officer
Ian McLeod Controller, Chief Financial & Accounting Officer
Thorsten Siess Chief Technology Officer
Seth Bilazarian Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABIOMED, INC.65.96%8 461
THERMO FISHER SCIENTIFIC INC.29.31%74 976
DANAHER19.14%64 816
INTUITIVE SURGICAL74.80%42 534
ROYAL PHILIPS11.71%36 093
BOSTON SCIENTIFIC CORPORATION15.30%35 387